Evidence map›Paper›PMID 32904569›Full record

ArticleOncoTargets and therapy2020

USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer.

Zhe Dong, Shuai Guo, Yue Wang, Jun Zhang, Haojie Luo, Guoliang Zheng, Dong Yang, Tao Zhang, Liucun Yan, Li Song and 6 more

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Network pharmacology study andWorld journal of gastrointestinal oncology · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Zhe Dong *Postgraduate School of China Medical University, Shenyang 110001, Liaoning Province, People's Republic of China.
Shuai Guo *Postgraduate School of China Medical University, Shenyang 110001, Liaoning Province, People's Republic of China.
Yue WangDepartment of Stomach Surgery, Cancer Hospital of China Medical University (Liaoning Cancer Hospital and Institute), Shenyang 110042, Liaoning Province, People's Republic of China.
Jun ZhangDepartment of Stomach Surgery, Cancer Hospital of China Medical University (Liaoning Cancer Hospital and Institute), Shenyang 110042, Liaoning Province, People's Republic of China.
Haojie LuoPostgraduate School of China Medical University, Shenyang 110001, Liaoning Province, People's Republic of China.
Guoliang ZhengDepartment of Stomach Surgery, Cancer Hospital of China Medical University (Liaoning Cancer Hospital and Institute), Shenyang 110042, Liaoning Province, People's Republic of China.
Dong YangDepartment of Stomach Surgery, Cancer Hospital of China Medical University (Liaoning Cancer Hospital and Institute), Shenyang 110042, Liaoning Province, People's Republic of China.
Tao ZhangDepartment of Stomach Surgery, Cancer Hospital of China Medical University (Liaoning Cancer Hospital and Institute), Shenyang 110042, Liaoning Province, People's Republic of China.
Liucun YanYidu Cloud (Beijing) Technology Co., Ltd., Beijing 100083, People's Republic of China.
Li SongYidu Cloud (Beijing) Technology Co., Ltd., Beijing 100083, People's Republic of China.ORCID 0000-0003-3502-3803
Kejia LiuYidu Cloud (Beijing) Technology Co., Ltd., Beijing 100083, People's Republic of China.
Zhe SunYidu Cloud (Beijing) Technology Co., Ltd., Beijing 100083, People's Republic of China.
Xiangyu MengDepartment of Stomach Surgery, Cancer Hospital of China Medical University (Liaoning Cancer Hospital and Institute), Shenyang 110042, Liaoning Province, People's Republic of China.ORCID 0000-0002-6876-0028
Zhichao ZhengDepartment of Stomach Surgery, Cancer Hospital of China Medical University (Liaoning Cancer Hospital and Institute), Shenyang 110042, Liaoning Province, People's Republic of China.
Jianjun ZhangDepartment of Stomach Surgery, Cancer Hospital of China Medical University (Liaoning Cancer Hospital and Institute), Shenyang 110042, Liaoning Province, People's Republic of China.
Yan ZhaoDepartment of Stomach Surgery, Cancer Hospital of China Medical University (Liaoning Cancer Hospital and Institute), Shenyang 110042, Liaoning Province, People's Republic of China.
Liaoning Cancer Hospital & Institute · CNChina Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo investigate the clinical significance of ubiquitin-specific peptidase 19 (USP19) expression in gastric cancer (GC) compared with that in normal tissues and gastric cell lines.

methodsUSP19 protein expression was analyzed in 212 paired GC samples using immunohistochemical staining. Quantitative real-time PCR (qRT-PCR) and Western blotting were used to detect the level of USP19 in gastric cell lines. The biological functions of USP19 were investigated by MTT assay, colony-forming assay, wound healing assay and gelatin zymography, and apoptotic cells were detected by immunohistochemistry assays in SGC7901 xenograft models.

resultsUSP19 expression was significantly increased in GC cells and tissues, and the high level of USP19 expression was positively correlated with the Lauren's classification and poor prognosis. Moreover, USP19 was identified as a novel independent prognostic biomarker in GC patients. Enhanced USP19 expression promoted GC cell proliferation and metastasis through reduced cleaved caspase-3 and increased MMP2/MMP9 expression and promoted enzyme activity in the study, and verified the results through The Cancer Genome Atlas (TCGA) and bioinformatic websites from the Kaplan-Meier plotter (http://kmplot.com) and GEPIA (http://gepia2.cancer-pku.cn.).

conclusionOur study suggests that USP19 promoted tumor progression by inducing MMP2/MMP9 expression and related enzyme activity. Hence, USP19 may be a valuable prognostic predictor for GC, and the USP19-MMP2/MMP9 axis could serve as a therapeutic target.

Indexed as

gastric cancerinvasionmetastasisMMP2/MMP9prognosisTCGAUSP19

Identifiers

PMID32904569
PMCPMC7457554
OpenAlexW3081294609

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.